APA (7th ed.) Citation

Munster, P. N., Marchion, D., Thomas, S., Egorin, M., Minton, S., Springett, G., . . . Daud, A. (2009). Phase I trial of vorinostat and doxorubicin in solid tumours: Histone deacetylase 2 expression as a predictive marker. British Journal of Cancer, 101(7), 1044. https://doi.org/10.1038/sj.bjc.6605293

Chicago Style (17th ed.) Citation

Munster, P. N., et al. "Phase I Trial of Vorinostat and Doxorubicin in Solid Tumours: Histone Deacetylase 2 Expression as a Predictive Marker." British Journal of Cancer 101, no. 7 (2009): 1044. https://doi.org/10.1038/sj.bjc.6605293.

MLA (9th ed.) Citation

Munster, P. N., et al. "Phase I Trial of Vorinostat and Doxorubicin in Solid Tumours: Histone Deacetylase 2 Expression as a Predictive Marker." British Journal of Cancer, vol. 101, no. 7, 2009, p. 1044, https://doi.org/10.1038/sj.bjc.6605293.